CSL Ltd. — Regulatory Filings 2020

May 26, 2020

For immediate release

==> picture [205 x 32] intentionally omitted <==

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

27 May 2020

CSL leases Swiss biotech manufacturing facility to Thermo Fisher Scientific

CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has entered into a strategic partnership with Thermo Fisher Scientific, the world leader in serving science, for the lease of its state-of-the-art biotech manufacturing facility currently under construction in Lengnau, Switzerland, and contracting of capabilities and capacities from within the Thermo Fisher network.

This follows a strategic review by CSL to determine a pathway that would fully optimise the capabilities of the Lengnau facility once construction is completed in 2021.

CSL and Thermo Fisher have entered into a long-term agreement. This includes Thermo Fisher leasing and operating the Lengnau facility and being responsible for providing production to support CSL’s biologics portfolio, as well a variety of other contract manufacturing services such as packaging and fill-and-finish for a number of CSL products.

CSL commenced construction of its Lengnau facility in 2015 with the intent of satisfying the commercial production of three next-generation recombinant products: AFSTYLA[®] (Factor VIII), IDELVION[®] (long-acting Factor IX) and CSL689 (long-acting Factor VIIa). Since then, CSL’s development of CSL689 has been discontinued and the competitive landscape for AFSTYLA[® ] has changed significantly.

CSL Chief Operating Officer Paul McKenzie said, “As part of the strategic review, we are in the process of transforming our end-to-end supply chain with a view to ensuring the company’s global manufacturing network is operating at a best-in-class level. This includes balancing internal investment with access to capabilities and capacities that are available with an experienced partner.

“CSL will now be able to access a wide range of capabilities provided by a leading pharma services provider, and we are confident that the management of the facility and the team will be in the very best of hands,” he said.

CSL and Thermo Fisher have a longstanding relationship. Thermo Fisher has been an important provider of third-party services to CSL including for fill-and-finish, cell culture growth media, single-use technologies and laboratory instruments and supplies.

==> picture [99 x 7] intentionally omitted <==

==> picture [58 x 30] intentionally omitted <==

==> picture [262 x 27] intentionally omitted <==

Page 2

While the agreement has no material impact to CSL’s FY20 guidance, it has been disclosed to shareholders due to the strategic nature of the arrangement.

Authorised by Fiona Mead Company Secretary

FURTHER INFORMATION

For further information, please contact:

Investors: Mark Dehring Head of Investor Relations CSL Limited Telephone: +613 9389 3407 Email: mark.dehring@csl.com.au

Media: Jemimah Brennan Head of Communications Asia Pacific CSL Limited Mobile +61 412 635 483 Email: jemimah.brennan@csl.com.au

® Trademarks of CSL Limited or its affiliates.

==> picture [99 x 7] intentionally omitted <==